Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 10, 2009, Pages 1137-1145

  Adams, Heiner ^a   Campidelli, Cristina ^b   Dirnhofer, Stephan ^a   Pileri, Stefano A ^b   Tzankov, Alexandar ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Unit of Hematopathology   (Italy)

Author keywords

B cell signature; Background infiltrate; Hodgkin lymphoma; PTLD

Indexed keywords

AZATHIOPRINE; BLEOMYCIN; CD15 ANTIGEN; CD30 ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; GRANZYME B; IMMUNOGLOBULIN; JANUS KINASE 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTAMER TRANSCRIPTION FACTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; STAT3 PROTEIN; TACROLIMUS; VINBLASTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GENE REARRANGEMENT; GENETIC ANALYSIS; HODGKIN DISEASE; HUMAN; IMMUNOCOMPETENCE; MALE; PHENOTYPE; PROTEIN EXPRESSION; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 70349386193     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903196779     Document Type: Article

References (45)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edition. IARC Press, Geneva, 2008
2. Pitman SD, Huang Q, Zuppan CW, et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006;30:470-476 • Most relevant case series (5 cases) and literature review on Hodgkin lymphoma-like post-transplant lymphoproliferative disorder. (Pubitemid 43740148)
3. Ranganathan S, Jaffe R. Is there a difference between Hodgkin's disease and a Hodgkin's-like post-transplant lymphoproliferative disorder, and why should that be of any interest? Pediatr Transplant 2004;8:6-8
4. Ranganathan S, Webber S, Ahuja S, et al. Hodgkin-like posttransplantlymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma? Pediatr Dev Pathol 2004;7:348-360
5. Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 2007;14:189-194 •• A most thorough review on immunodeficiency-related Hodgkin lymphomas with a particular diagnostic importance.
6. Nalesnik MA, Randhawa P, Demetris AJ, et al. Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer 1993;72:2568-2573 (Pubitemid 23320216)
7. Garnier JL, Lebranchu Y, Dantal J, et al. Hodgkin's disease after transplantation. Transplantation 1996;61:71-76 • The largest reported series, to our knowledge, (7 cases) of clinically well documented cases of Hodgkin lymphoma after solid organ transplantation.
8. Caillard S, Agodoa LY, Bohen EM, et al. Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006;81:888-895
9. Conter V, Tschümperlin B, Gridelli B, et al. Hodgkin's disease occurring in a child after liver transplantation. Ann Oncol 1998;9:673-676 (Pubitemid 28318203)
10. Dharnidharka VR, Douglas VK, Hunger SP, et al. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant 2004;8:87-90 (Pubitemid 38139792)
11. Stern M, Herrmann R, Rochlitz C, et al. A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma. Eur J Haematol 2005;74:267-270 (Pubitemid 40278499)
12. Choi JH, Ahn MJ, Oh YH, et al. Epstein-Barr virus-associated Hodgkin's disease following renal transplantation. Korean J Intern Med 2006;21:46-49 (Pubitemid 43732767)
13. Flanagan KH, Brennan DC. EBV-associated recurrent Hodgkin's disease after renal transplantation. Transpl Int 2006;19:338-341
14. Tzankov A, Zimpfer A, Pehrs AC, et al. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003;11:1141-1147 • The, to our knowledge, largest (253 evaluable cases) phenotypic study of CD20 and CD79a expression in classical Hodgkin lymphoma with 33% CD20- and 10% CD79a-positive cases. (Pubitemid 37414209)
15. Meier C, Hoeller S, Bourgau C, et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009;22:476-487
16. Tzankov A, Bourgau C, Kaiser A, et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol 2005;18:1542-1549 • To our knowledge, the largest (259 evaluable cases) phenotypic study of T-cell marker expression in classical Hodgkin lymphoma with 5% T-cell marker-positive cases. (Pubitemid 41670652)
17. Muenst S, Hoeller S, Dirnhofer S, et al. Increased PD-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009, doi:10.1016/j.humpath.2009.03.025
18. Hoeller S, Zihler D, Zlobec I, et al. BOB.1, CD79a and Cyclin E are the most appropriate markers to discriminate classical Hodgkin lymphoma from primary mediastinal large B-cell lymphoma. Histopathology 2009; accepted for publication
19. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200
20. Bellas C, Santon A, Manzanal A, et al. Pathological, immunological, and molecular features of Hodgkin's disease associated with HIV infection. Comparison with ordinary Hodgkin's disease. Am J Surg Pathol 1996;20:1520-1524 • Similarly to our post-transplant Hodgkin lymphoma, all Hodgkin lymphoma cases in the setting of HIV infection were associated with Epstein-Barr virus infection. (Pubitemid 26411721)
21. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999;93:2319-2326 (Pubitemid 29153635)
22. Thompson LD, Fisher SI, Chu WS, et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol 2004;121:727-738 (Pubitemid 38534005)
23. Flavell KJ, Murray PG. Hodgkin's disease and the Epstein-Barr virus. Mol Pathol 2000;53:262-269
24. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004;200:1623-1633 (Pubitemid 40094186)
25. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007;110:2620-2630 (Pubitemid 47523186)
26. García-Cosío M, Santón A, Martín P, et al. Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma. Mod Pathol 2004;17:1531-1538
27. McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol 2006;19:1010-1018
28. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-4289
29. Rehwald U, Schulz H, Reiser M, et al. German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody Rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003;101:420-424
30. Davis JE, Moss DJ. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004;63:285-292
31. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody Rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-2906 (Pubitemid 43923950)
32. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685-1691 (Pubitemid 29262850)
33. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297 •• A most thorough review on the role of cytokine signaling pathways in Hodgkin lymphoma.
34. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006;108:3786-3791 •• A very interesting observation that Hodgkin lymphoma incidence is lower with severe immunosuppression than with moderate immunosuppression in HIV-infected patients, which can explain why HAART-related improvements in CD4 counts are accompanied by increasing Hodgkin lymphoma rates. The authors raise an elegant hypothesis that CD4 depletion may hint Hodgkin lymphomagenesis by withdrawal of essential feedback signals from the inflammatory cellular background.
35. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:407-409 (Pubitemid 40528605)
36. ten Berge RL, Oudejans JJ, Dukers DF, et al. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia 2001;15:458-464
37. Alvaro T, Lejeune M, Salvadó MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-1473 (Pubitemid 40315228)
38. Bosch Príncep R, Lejeune M, Salvadó Usach MT, et al. Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann Hematol 2005;84:661-666
39. Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of Rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006;7:285-294 (Pubitemid 44043658)
40. Vaysberg M, Balatoni CE, Nepomuceno RR, et al. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 2007;83:1114-21 •• In vitro evidence of the therapeutic potential of Rapamycin in Epstein-Barr virus-associated lymphoproliferations is presented. (Pubitemid 46659124)
41. Dancey JE. Therapeutic targets: mTOR and related pathways. Cancer Biol Ther 2006;5:1065-1073
42. Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005;205:498-506 (Pubitemid 40361339)
43. Jundt F, Raetzel N, Müller C. A rapamycin derivative (Everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein aβ and NF-eβB activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005;106:1801-7 •• In vitro and in vivo (xenograft models) evidence of the therapeutic potential of Everolimus in Hodgkin lymphoma is presented.
44. Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009;113:1723-1729
45. Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 2005;19:936-944 (Pubitemid 40862003)